Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

It demonstrated that the antibody with standard of care (SOC) significantly improved disease control over 24 weeks against placebo plus SOC, as assessed by the Myasthenia Gravis-Activities of ...

"FDA's approval of IMAAVY TM (nipocalimab-aahu) is an important step in expanding treatment options for people living with myasthenia gravis,” said Donald S. Wood, PhD, President and CEO, MDA. "With ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years.

The FDA has approved the J&J drug, known in development as nipocalimab, as a treatment for generalized myasthenia gravis (gMG). The regulatory decision announced Wednesday could be the first of ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Pineal Pure is a leading nootropic and detox supplement formulated to support pineal gland health, enhance memory function, and promote long-term brain clarity. The pineal gland, often called the ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy. The FDA has approved Johnson and Johnson’s Imaavy (nipocalimab-aahu), the first ...

The safety profile of J&J’s antibody was consistent across the Vivacity-MG3 and the ongoing Vibrance-MG trials. Credit: Manuel Esteban/Shutterstock. Johnson & Johnson’s (J&J) human neonatal Fc ...

Johnson & Johnson’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The drug will be marketed under the brand name Imaavy. With the approval, J&J is ...